Cell & gene therapy sponsor
Advanced therapy · preparing a first licence application
A sponsor approaching its first biologics licence application and pre-license inspection, with manufacturing split across contract sites and no consolidated view of CMC risk.
Built a deficiency register covering drug substance and drug product, mapped every item to the governing CFR, ICH and EU GMP requirement, then ran mock inspections against the gaps rather than against a checklist.
A single ranked risk picture the sponsor could work through by owner and date, and SMEs who had already answered the hard questions once before an investigator asked them.